Hard To Treat Diseases (HTDS) Corporate Update

TORONTO, Dec. 29 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS)
www.htdsmedical.com (site under construction) is pleased to announce that it
has appointed a new interim management. In addition the company has identified
a suitable merger operating candidate. The merger candidate is a China based
bio chemical company.
As well, the company in the unlikely event of a non completion with the China
based medical company is also continuing its negotiations with an East
European medical company whose primary focus involves the enhancement and
modification of existing approved drugs such as "Virazole" for the purpose of
chemical repair of damage to the CNS (central nervous system), MS (Multiple
Sclerosis), SARS, Hepatitis C and HIV.
Mr. Keith Roberts the company's interim CEO said "We are looking in all
directions for the best opportunities. Our stock is at the lowest price
possible and we are resisting all suggestions of any stock splits. We believe
that as a Pink Sheet company we can provide the lift to HTDS that will give
our shareholders the best return. The China company seems to be the most
appealing and possibly may offer the biggest growth however we are not
discounting the opportunity with the Europe medical company. It may very well
be that we end up with both operating companies. We expect to be able to close
either one or both of these deals in the first quarter of 2009".
The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of
1995: Certain information contained in this release contains forward-looking
statements that involve risk and uncertainties, including but not limited to,
those relating to development and expansion activities, domestic and global
conditions, and market competition.

CONTACT: corporate@htdsmedical.com

CONTACT: corporate@htdsmedical.com

SOURCE Hard to Treat Diseases (HTDS)

corporate@htdsmedical.com